RxDoctor Payments Data

Martha Montanez, MD

Family Medicine · El Paso, TXNPI 1164805420

Payments from drug & device makers

$3,150in general payments, 2019–2025

Across 81 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$800
  • Novo Nordisk$578
  • Lilly USA, LLC$399
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$302
  • Bayer$269
  • Boehringer Ingelheim$210
  • plus $591 from 9 others

What the payments were for

  • Food & beverage$3,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,150 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$57,644
Medicare patients
235
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide135$162,046
FarxigaDapagliflozin Propanediol54$52,371
TrulicityDulaglutide26$52,035
JardianceEmpagliflozin48$44,090
RybelsusSemaglutide26$35,366
EliquisApixaban37$19,101
OzempicSemaglutide15$12,900
Atorvastatin Calcium200$2,179
Losartan Potassium146$1,406
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,174
Omega-3 Acid Ethyl Esters12$1,143
Albuterol Sulfate HfaAlbuterol Sulfate39$1,001
Fluticasone Propionate67$944
Omeprazole39$783
Metformin Hcl131$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$399$214,081161 claims
AstraZenecaFarxiga$800$52,37154 claims
Novo NordiskRybelsus, Ozempic$578$48,26641 claims
Boehringer IngelheimJardiance$210$44,09048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →